Assessing Functional Quality of Single TILs for Correlative Immunotherapy Biomarkers
Learn how using Single-Cell PSI™ can help you reveal mechanism in the Tumor Microenvironment.
Challenge: Checkpoint combination studies need TILs solutions
Recently, checkpoint inhibitor blockade therapy has rapidly advanced and is now established as a powerful way to manage various malignant tumors. Despite the promising outcomes, there are a significant number of patients who do not respond to these immunotherapies.
In this Application Note we:
- Highlight the challenges in functional characterization of TILs in checkpoint and combination therapies
- Describe the workflow for functional single-cell analysis from both solid tumor TILs as well as patient PBMC
- Predict patient response to checkpoint therapy using PSI as a biomarker in solid tumor TILs, as well as correlate response from these solid tumor TILs with PSI from peripheral blood